Provided by Tiger Trade Technology Pte. Ltd.

Nuvation Bio, Inc.

6.93
+0.10001.46%
Post-market: 6.90-0.0300-0.43%19:50 EDT
Volume:6.04M
Turnover:42.23M
Market Cap:2.43B
PE:-15.80
High:7.09
Open:6.98
Low:6.88
Close:6.83
52wk High:9.75
52wk Low:2.76
Shares:351.12M
Float Shares:264.00M
Volume Ratio:0.72
T/O Rate:2.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4387
EPS(LYR):-0.6000
ROE:-47.81%
ROA:-12.36%
PB:9.58
PE(LYR):-11.55

Loading ...

Nuvation Bio Q2 FY26 Revenue More than Doubled to $31.69 Million

Reuters
·
Aug 06

Nuvation Bio (NUVB) To Share New IBTROZI Data At Two Major Cancer Conferences

Simply Wall St.
·
Aug 05

Nuvation Bio to Present Subgroup Analyses from TRUST-I, TRUST-II Taletrectinib Studies in ROS1+ NSCLC at WCLC 2026

Reuters
·
Aug 04

Nuvation Bio is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 27

Nuvation Bio Inc. : H.c. Wainwright Raises Target Price to $21 from $17

THOMSON REUTERS
·
Jul 27

Nuvation Bio Price Target Maintained with a $11.00/share by Wedbush

Dow Jones
·
Jul 23

Nuvation Bio Schedules Q2 2026 Results Call, Business Update Webcast

Reuters
·
Jul 23

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

THOMSON REUTERS
·
Jul 23

Nuvation Bio's Safusidenib Clinical Program, Ibtrozi Opportunity Create Favorable Setup, RBC Says

MT Newswires Live
·
Jul 23

Nuvation Bio (NUVB) Could Be 48% Undervalued As Safusidenib Data Strengthens Its Case

Simply Wall St.
·
Jul 22

Sector Update: Healthcare

MT Newswires Live
·
Jul 21

U.S. Stocks on the Move-yum Brands, AMD, Nuvation Bio

Reuters
·
Jul 21

RBC looks for Nuvation shares to appreciate as safusidenib data builds

TIPRANKS
·
Jul 20

Nuvation Bio Rises as Brain Cancer Drug Data Spur Expansion of Studies

Reuters
·
Jul 20

Nuvation Bio Posts Corporate Deck Highlighting Ibtrozi ROS1+ NSCLC Launch, Safusidenib IDH1 Glioma Program

Reuters
·
Jul 20

Nuvation Bio announces data from the Phase 2 J201 study

TIPRANKS
·
Jul 20

Nuvation Bio Reports Updated Phase 2 Safusidenib Data, Expands Idh1-mutant Glioma Studies

Reuters
·
Jul 20

Nuvation Bio - Reports 52% Confirmed Objective Response Rate in Phase 2 Safusidenib Study

THOMSON REUTERS
·
Jul 20

Analysts’ Top Healthcare Picks: Argenx Se (ARGX), Nuvation Bio (NUVB)

TIPRANKS
·
Jul 13

Nuvation Bio is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 07